The DOI matches its Crossref record.
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS): 942
Abstract
Purpose: Recent evidence implicates the GI microbiota in the progression of neurological diseases such as Parkinsons Disease1, Multiple Sclerosis and Myasthenia Gravis2. We report three patients with MS diagnoses who achieved durable symptom reversal with FMT for constipation. Methods: Case study observations on three MS cases Results: Case 1: A 30 yr old male with constipation, vertigo and impaired concentration and a concomitant history of MS and trigeminal neuralgia. Neurological symptoms included severe leg weakness and he required a wheelchair and an indwelling urinary catheter. Previous failed treatments included Mexiletine, Tryptanol and β-interferon. The patient underwent 5 FMT infusions for his constipation, with its complete resolution. Interestingly his MS also progressively improved, regaining the ability to walk and facilitating the removal of his catheter. Initially seen as a ‘remission', the patient remains well 15 yrs post-FMT without relapse. Case 2: A 29 yr old wheelchair-bound male with ‘atypical MS' diagnosis and severe, chronic constipation. He reported parasthesia and leg muscle weakness. The patient received 10 days of FMT infusions which resolved his constipation. He also noted progressive improvement in neurological symptoms, regaining the ability to walk following slow resolution of leg parasthesia. Three years on the patient maintains normal motor, urinary and GI function. Case 3: An 80 yr old female presented with severe chronic constipation, proctalgia fugax and severe muscular weakness resulting in difficulty walking, diagnosed as ‘atypical' MS. She received 5 FMT infusions with rapid improvement of constipation and increased energy levels. At eight months she reported complete resolution of bowel symptoms and neurological improvement, now walking long distances unassisted. Two years post-FMT, the patient was asymptomatic. Conclusion: We report reversal of major neurological symptoms in three patients after FMT for their underlying GI symptoms. As MS can follow a relapsing-remitting course, this unexpected discovery was not reported until considerable time had passed to confirm prolonged remission. It is tempting to speculate that FMT achieved eradication of an occult GI pathogen driving MS symptoms. Our finding that FMT can reverse MS-like symptoms suggests a GI infection underpinning these disorders. It is hoped that such serendipitous findings may encourage a new direction in neurological research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an additional relevant study, three MS patients underwent multiple fecal microbiota transplantations (FMT) to treat severe constipation. This treatment reverted the intestinal illness and improved the MS symptoms (147), proving the existence of a gut-brain connection.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [147]
Citations
Cited by
Sorted by citations
Items 101–146 of 146
Ahmadi, S., Hasani, A., Khabbaz, A., Poortahmasebi, V., Hosseini, S., Yasdchi, M., Mehdizadehfar, E., Mousavi, Z. B., Hasani, R., Nabizadeh, E., et al. (2024) · Biogerontology · doi:10.1007/s10522-024-10136-4 · Cited by 9
“FMT technique has been studied successfully on cases in the treatment of MS (Borody et al. 2011), and depression (Kelly et al. 2016).”
Kawakami, N., & Wekerle, H. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00442 · Cited by 10
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00009-0 · Cited by 8
Current Paradigms to Explore the Gut Microbiota Linkage to Neurological Disorders
Sharma, V., Sankhyan, A., Varshney, A., Choudhary, R., & Sharma, A. K. (2020) · EMJ Neurology · doi:10.33590/emjneurol/20-00068 · Cited by 9
Contemporary Topics in Patient Safety - Volume 1
Stawicki, S. P., & Firstenberg, M. S. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87616 · Cited by 8
The Human Gut Microbiome and Its Role in Obesity and the Metabolic Syndrome
Mullin, G. E., & Delzenne, N. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0548-5_7 · Cited by 7
Safety and Potential Risks with Fecal Microbiota Transplantation
Gaonkar, P. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95907 · Cited by 7
Boeije‐Koppenol, E., Terveer, E. M., Vendrik, K. E. W., van Lingen, E., Verspaget, H. W., Keller, J. J., Kuijper, E. J., & Giltay, E. J. (2022) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2022.100355 · Cited by 10
Ternák, G., Édel, Z., Feiszt, Z., Szekeres, J., Visegrády, B., & Wittmann, I. (2015) · Health · doi:10.4236/health.2015.710145 · Cited by 5
“The amelioration of the symptoms and the improvement of insulin resistance were achieved in many cases [28] [29].”
BackgroundGut Microbiome as Potential Therapeutics in Multiple Sclerosis
Zhu, W., Dykstra, K., Zhang, L., & Xia, Z. (2021) · Current Treatment Options in Neurology · doi:10.1007/s11940-021-00693-1 · Cited by 7
Gut microbiota: a potential influencer of insomnia occurring after COVID-19 infection
Fang, J., Wang, S., Liu, L., Zhang, X., Liu, R., Pang, X., Cui, J., Han, J., & Zhu, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1423715 · Cited by 4
Tiburcio, Á. Z. (2019) · Gastroenterology Medicine & Research · doi:10.31031/gmr.2019.03.000551 · Cited by 4
Ladakis, D. C., & Bhargava, P. (2023) · CNS Drugs · doi:10.1007/s40263-023-00986-w · Cited by 6
“2 Humans Until recently the only evidence that existed about FMT in MS consisted of two case studies during which FMT was performed for treating MS-related constipation (three people) [94] and C.”
BackgroundRussian experience in fecal microbiota transplantation
Vlassov, V. V., & Morozov, V. V. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-212-4-113-120 · Cited by 3
Fecal microbiota transplantation for glaucoma; a potential emerging treatment strategy
Ebrahimi, R., Farsi, Y., & Nejadghaderi, S. A. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100314 · Cited by 4
Faecal microbiota transplant – prospects and safety
Bartnicka, A., Szachta, P., & Gałęcka, M. (2016) · Pomeranian Journal of Life Sciences · doi:10.21164/pomjlifesci.98 · Cited by 3
“obesity [35], insulin resistance, metabolic syndrome [36], Par‐ kinson’s disease [37], chronic fatigue syndrome [38], multiple sclerosis [39], myoclonus dystonia [40], and childhood regres‐ sive autism [41].”
BackgroundRompiendo paradigmas. Trasplante de microbiota intestinal: reporte preliminar
Zamudio-Tiburcio, Á., Bermúdez-Ruiz, H., Lezama-Guzmán, H. R., Guevara-Ortigoza, M. D. P., Islas-Solares, E., & Sosa-López, F. A. (2017) · Cirugía y Cirujanos · doi:10.1016/j.circir.2016.11.017 · Cited by 3
DISBIOSIS CORRECTION - THE BASIS OF REGENERATIVE MEDICINE
Mikhailova, N. A., Voevodin, D. A., & Поддубиков, А. В. (2018) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-2018-5-107-113 · Cited by 2
Ткач, С. М., Dorofeyev, A., Kuzenko, I., Boyko, N., Falalyeyeva, T. M., & Kobyliak, N. M. (2023) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-031-19564-8_10 · Cited by 2
Dedeepiya, V. D., Vetrievel, C., Ikewaki, N., Yamamoto, N., Kawashima, H., Ichiyama, K., Senthilkumar, R., Preethy, S., & Abraham, S. J. (2023) · medRxiv · doi:10.1101/2023.09.07.23295172 · Cited by 3
Gut Microbiome Transplants and Their Health Impacts across Species
Levine, B. H., & Hoffman, J. M. (2023) · Microorganisms · doi:10.3390/microorganisms11061488 · Cited by 6
Gut microbiota modification as an option in multiple sclerosis management
Zwiernik, B., Arłukowicz, T., Mycko, M. P., & Zwiernik, J. (2020) · Polish Annals of Medicine · doi:10.29089/2020.20.00133 · Cited by 2
Fecal transplantation: clinical realities and prospects in the treatment of metabolic syndrome
Sas, E. I., Grinevich, V. B., & Barnakova, V. A. (2020) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-183-11-102-112 · Cited by 2
“Это интересное влияние кишечника на центральную нервную систему наблюдалось у людей с почти полной и продолжительной (> 15 лет) нормализацией ранее задокументированных тяжелых симптомов рассеянного склероза у 3 пациентов, перенесших FMT от запора [85].”
Gut microbiota alterations and nutritional intervention in multiple sclerosis disease
Noguera-Navarro, C., Navas-Carrillo, D., & Orenes‐Piñero, E. (2022) · Food Reviews International · doi:10.1080/87559129.2022.2062771 · Cited by 2
Bakker, G. J., & Nieuwdorp, M. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch12 · Cited by 2
Lateral Amyotrophic Sclerosis and Intestinal Microbiota Transplantation
Tiburcio, Á. Z. (2019) · Gastroenterology Medicine & Research · doi:10.31031/gmr.2019.03.000558 · Cited by 1
Role of Gastrointestinal Dysbiosis and Fecal Transplantation in Parkinson’s Disease
Jena, R., Jain, R., Muralidharan, S., Yanamala, V. L., Zubair, Z., Kantamaneni, K., Jalla, K., Renzu, M., & Alfonso, M. (2021) · Cureus · doi:10.7759/cureus.19035 · Cited by 1
Malygina, D., Alexander, V., Olga, Z., Vorobyova, O., Dmitry, P., Daria, Z., & Anna, B. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2021.120201 · Cited by 1
Could ancient Yamnaya dairying explain the environmental component of multiple sclerosis?
Rumah, K. R. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111360 · Cited by 1
The Microbiota and Its Modulation in Immune-Mediated Disorders
Pevsner‐Fischer, M., Rot, C., Tuganbaev, T., & Elinav, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803302-9.00010-5 · Cited by 1
The Role of the Indigenous Gut Microbiota in Human Health and Disease
Vunk, T. R., & Burkholder, K. M. (2017) · Advances in environmental microbiology · doi:10.1007/978-3-319-60616-3_4 · Cited by 1
Characterization of Intestinal Microbiota in Healthy Adults and the Effect of Perturbations
Jalanka, J. (2014) · Työväentutkimus Vuosikirja · Cited by 1
Armstrong, C. W. (2017) · Minerva Access (University of Melbourne) · Cited by 1
Davey, K. J. (2013) · Cork Open Research Archive (University College Cork, Ireland)
Advances in Gastrointestinal Surgery
Chattopadhyay, T. K. (2015) · GI surgery annual · doi:10.1007/978-981-10-2010-0_10
Transplantatie van fecale microbiota : oude wijn in nieuwe zakken?
Holvoet, T., de Wiele, T. V., Boelens, J., Raes, J., Hindryckx, P., Vos, M. D., & Looze, D. A. D. (2014) · Ghent University Academic Bibliography (Ghent University)
Koleilat, A. (2017) · Gastroenterology & Hepatology International Journal · doi:10.23880/ghij-16000131
The future of microbiome research in neuroinflammatory disorders
Waubant, E. L., Pröbstel, A., Levy, M., Hawkes, C. H., Giovannoni, G., Lechner‐Scott, J., & Tremlett, H. L. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102098
FECAL MICROBIOTES TRANSPLANTATION TECHNOLOGIES: MEDICAL, BIOTECHNOLOGICAL AND REGULATORY ASPECTS
Bakalchuk, M. M. (2021) · Biotechnologia Acta · doi:10.15407/biotech14.01.46
Gut Microbiota in Brain diseases
Salami, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00040-1
Research Progress of Intestinal Flora and Neurological Diseases
邹, 嫄. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.121093
Ren, L., Xu, D., Zhang, W., Wu, S., Yu, M., He, X., & Wei, Z. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4530808
Neurological Disorders and the Gut-Brain Axis
Chattopadhyay, M., Laskar, A., Rahaman, S. S., & Chanda, A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324549125010010
Bhattacharya, A., Agarwal, K., Ganguly, N. K., & Suroliya, V. (2025) · Next research. · doi:10.1016/j.nexres.2025.100441
The gut microbiota–miRNA axis in multiple sclerosis: Mechanisms and therapeutic potentials
Sedaghat, F. R., Hasani, A., Poortahmasebi, V., Hosseini, S., Kafil, H. S., Heydarlou, M. M., Ahmadi, S., Mehdizadehfar, E., Sadeghpour, Y., Hasani, R., et al. (2026) · Folia Microbiologica · doi:10.1007/s12223-026-01574-3
Metadata
- Authors
- Borody, T., Leis, S., Campbell, J., Torres, M., & Nowak, A.
- Affiliations
- Centre For Digestive Diseases (AU)
- Venue
- American Journal of Gastroenterology
- Published
- 2011-10
- Volume
- 106
- Pages
- S352
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2978324930
- Cited by
- 149
- References
- 0
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 11 · 2023: 17 · 2022: 15 · 2021: 22 · 2020: 14 · 2019: 7 · 2018: 8 · 2017: 16 · 2016: 9 · 2015: 7 · 2014: 5 · 2013: 9 · 2012: 2
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- fecal microbiota transplantation, multiple sclerosis, chronic constipation, proctalgia fugax, gut microbiota, urinary catheter removal, relapsing-remitting multiple sclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review